Lead asset shows systemic, dose‑dependent anti‑tumour activity
News
Theolytics announces first patient dosed in the Octopod‑IP trial
US study marks company’s second clinical trial of ovarian cancer therapy
UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
Clesrovimab is first monoclonal antibody offering a single fixed dose for infants
Saphnelo approved in the US for subcutaneous self‑administration
Greater flexibility for people with systemic lupus erythematosus
Transgene completes randomisation in phase 2 trial of tg4050
Company expects two‑year dfs data by q1 2028
Bayer wins MHRA approval for Kerendia in heart failure
New authorisation offers additional option for patients with lvef ≥40%
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
Partnership to develop next‑generation T‑cell engagers for solid tumours
Kainova expands DT 7012 trial into Europe
First patient dosed as DOMISOL study grows beyond Australia
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
Study expands development of the antibody into hepatocellular carcinoma
FDA approves new high dose Spinraza regimen for SMA
Updated dosing offers meaningful clinical benefit
Viridian reports positive results from elegrobart phase 3 trial
Company says treatment shows strong efficacy and convenient dosing profile
Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
Specialist group to review preclinical and clinical proposals ahead of funding decision
Kygevvi approved in Europe as first treatment for TK2d
European Commission authorises therapy for children and adults with early‑onset disease
Tozorakimab shows significant benefit in two major COPD trials
Phase 3 studies report meaningful reductions in exacerbations across broad patient groups
